Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EUROPEAN RESTRICTIONS ON USE OF Rx BRANDNAME FOR OTC SWITCH PRODUCT

This article was originally published in The Tan Sheet

Executive Summary

EUROPEAN RESTRICTIONS ON USE OF Rx BRANDNAME FOR OTC SWITCH PRODUCT poses a threat to the success of the Rx-to-OTC switch movement abroad, Berndt van Till, the incoming president of the European Proprietary Medicines Manufacturers Association (AESGP), suggested June 16 at the group's annual meeting in London. He noted that "restrictions with regard to the use of trademarks" in Europe represent a "barrier" to the "increasing trend to switch ingredients from prescription to nonprescription status."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082971

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel